Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 13, 2015, Pages 4068-4073

  Zamolodchikov, Daria ^a   Chen, Zu Lin ^a   Conti, Brooke A ^a   Renné, Thomas ^b,c   Stricklan, Sidney ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Alzheimer's disease; Factor XII; High molecular weight kininogen; Plasma kallikrein

Indexed keywords

AMYLOID BETA PROTEIN; BLOOD CLOTTING FACTOR 12; BRADYKININ; KALLIKREIN; KININOGEN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 12A; PEPTIDE FRAGMENT; TRANSFERRIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; AGED; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; DEMENTIA; DISEASE COURSE; DISEASE MODEL; FEMALE; GENETICS; MALE; METABOLISM; MOUSE; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; VERY ELDERLY;

MUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; DEMENTIA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FACTOR XII; FACTOR XIIA; FEMALE; HUMANS; INFLAMMATION; KALLIKREINS; KININOGENS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDE FRAGMENTS; TRANSFERRIN;

EID: 84961290482     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423764112     Document Type: Article

References (52)

1. von Bernhardi R (2007) Glial cell dysregulation: A new perspective on Alzheimer disease. Neurotox Res 12(4):215-232.
2. Wyss-Coray T (2006) Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat Med 12(9):1005-1015.
3. Träger U, Tabrizi SJ (2013) Peripheral inflammation in neurodegeneration. J Mol Med (Berl) 91(6):673-681.
4. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57(1):27-77.
5. Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C (2012) In vivo roles of factor XII. Blood 120(22):4296-4303.
6. Shibayama Y, et al. (1999) Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin Immunol 90(1):89-99.
7. Maas C, et al. (2008) Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118(9):3208-3218.
8. Bergamaschini L, et al. (2001) The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging 22(1):63-69.
9. Yasuhara O, Walker DG, McGeer PL (1994) Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease. Brain Res 654(2):234-240.
10. Ashby EL, Love S, Kehoe PG (2012) Assessment of activation of the plasma kallikreinkinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. Neurobiol Aging 33(7):1345-1355.
11. Bergamaschini L, et al. (1998) Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 12(2):102-108.
12. Pimentel-Coelho PM, Rivest S (2012) The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease. Eur J Neurosci 35(12):1917-1937.
13. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43(11):2412-2414.
14. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-198.
15. Hyman BT (1998) New neuropathological criteria for Alzheimer disease. Arch Neurol 55(9):1174-1176.
16. Squitti R, et al. (2010) Ceruloplasmin/Transferrin ratio changes in Alzheimer's disease. Int J Alzheimers Dis 2011:231595.
17. Müller F, et al. (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139(6):1143-1156.
18. Kannemeier C, et al. (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 104(15):6388-6393.
19. Renné T (2013) The FXII-driven Plasma Contact System. Hemostasis and Thrombosis. Basic Princeples and Clinical Practice, eds Marder V, Aird WC, Bennett JS, Schulman S, White, II GC (Wolters Kluwer, Philadelphia, PA), Vol 6, pp 242-253.
20. Mirra SS, et al. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4):479-486.
21. Musiek ES, Holtzman DM (2012) Origins of Alzheimer's disease: Reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol 25(6):715-720.
22. Silverberg M, Diehl SV (1987) The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate. The effect of the Mr of the activating polyanion. Biochem J 248(3):715-720.
23. Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL (1984) In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 63(6):1453-1459.
24. Pixley RA, Cassello A, De La Cadena RA, Kaufman N, Colman RW (1991) Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost 66(5):540-547.
25. Loeffen R, et al. (2012) Preanalytic variables of thrombin generation: Towards a standard procedure and validation of the method. J Thromb Haemost 10(12): 2544-2554.
26. Ramström S (2005) Clotting time analysis of citrated blood samples is strongly affected by the tube used for blood sampling. Blood Coagul Fibrinolysis 16(6):447-452.
27. Oakley H, et al. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26(40):10129-10140.
28. Ou-Yang MH, Van Nostrand WE (2013) The absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice. J Neuroinflammation 10:134.
29. Mayeux R, Schupf N (2011) Blood-based biomarkers for Alzheimer's disease: Plasma Aβ40 and Aβ 42, and genetic variants. Neurobiol Aging 32(Suppl 1):S10-S19.
30. Gabelle A, et al. (2013) Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study. J Alzheimers Dis 33(2):381-391.
31. Humpel C (2011) Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol 46(4):225-232.
32. Cardigan RA, Crook M, Mackie IJ, Machin SJ (2001) Plasma levels of factor XIIa and factor VIIa are increased but not related in primary hyperlipidaemia. Blood Coagul Fibrinolysis 12(3):187-192.
33. Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A (2010) Intrinsic coagulation activation and the risk of arterial thrombosis in young women: Results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) casecontrol study. Circulation 122(18):1854-1861.
34. Kohler HP, Carter AM, Stickland MH, Grant PJ (1998) Levels of activated FXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 79(1):14-18.
35. Weiser P, et al. (2010) Activated contact system and abnormal glycosaminoglycans in lupus and other auto- and non-autoimmune diseases. Prog Mol Biol Transl Sci 93: 443-472.
36. Pan J, et al. (2010) Glycosaminoglycans and activated contact system in cancer patient plasmas. Prog Mol Biol Transl Sci 93:473-495.
37. Cugno M, et al. (1997) Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89(9):3213-3218.
38. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1):a006346.
39. Farrall AJ, Wardlaw JM (2009) Blood-brain barrier: Ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 30(3):337-352.
40. Ryu JK, McLarnon JG (2009) A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 13(9A): 2911-2925.
41. Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81(2):229-248.
42. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12):723-738.
43. Olsson B, et al. (2013) Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis 33(1):45-53.
44. Carter SF, et al. (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11CPittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53(1):37-46.
45. Johnson KA, Albert MS (2000) Perfusion abnormalities in prodromal AD. Neurobiol Aging 21(2):289-292.
46. Wierenga CE, Hays CC, Zlatar ZZ (2014) Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. J Alzheimers Dis 42(Suppl 4):S411-S419.
47. de la Torre JC (2012) Cerebral hemodynamics and vascular risk factors: Setting the stage for Alzheimer' s disease. J Alzheimers Dis 32(3):553-567.
48. Larsson M, et al. (2014) A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 6(222):222ra17.
49. Fagan AM, et al. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65(2):176-183.
50. Gallimore MJ, Friberger P (1982) Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma. Thromb Res 25(3):293-298.
51. Pauer HU, et al. (2004) Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 92(3):503-508.
52. Merkulov S, et al. (2008) Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 111(3):1274-1281.